Preclinical studies show that in mouse xenograft models of ER‐positive/HER2‐positive breast cancer, treatment with lapatinib alone or combined with trastuzumab leads to heightened ER activity, contributing to anti‐HER2 resistance.12 Here, ERBB2 is linked to breast cancer.